X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: The year that was… - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 10, 2008

    Pharma: The year that was…

    FY08 was a mixed year for Indian pharma companies. While the pricing pressure in the global generics market and the sharp appreciation of the rupee kept pharma companies on their toes, most of them barring the MNC pharma companies were able to log decent growth rates as compared to the previous two years both in revenues and profitability. In this article, we shall take a look at some of highlights of the year with respect to the sector and the outlook going forward.

    NCE R&D - Parting ways? Hiving off NCE R&D gathered momentum during the year as Nicholas Piramal, Ranbaxy and Wockhardt announcing their plans with respect to the same on the heels of Dr.Reddy's and Sun Pharma. The rationale behind this move is to mitigate risks from R&D, improve margins, de-risk the overall business model and secure funding for the new R&D company.

    Revenues - A mixed show: While some of the domestic pharma companies reported decent growth in revenues, the performance of the MNC pharma companies left a lot to be desired. Companies such as Ranbaxy, Wockhardt, Glenmark and Nicholas Piramal reported strong growth in revenues due to first-to-file opportunities, acquisitions and out-licensing R&D molecules. These were also instrumental in bolstering profits. That said, if one were to look at Dr.Reddy's, the company was at the receiving end as both sales and profits plummeted led by the high base effect in FY07 when the company had garnered the 180-day exclusivity period for three drugs. On the other hand all the MNC pharma companies fared poorly and were hampered by supply related issues, rising raw material prices and lack of any significant product launches.

    Sharp rupee appreciation: In the last few years, domestic pharma companies have been increasingly focusing on the exports markets of the US and the Europe to capitalise on the generics potential and also to mitigate the long-term impact of the likely slowdown of product launches in the domestic market in the future. Having said that, the sharp appreciation of the rupee against the dollar from US$ 45 levels to US$ 39.30 levels in the past one-year has dented topline performance of most of the domestic pharma companies for whom exports contribute around 50% to 80% to total revenues.

    Raw material worries: Pharma companies were witness to increasing raw material prices during the year. Many of them import intermediates (used for making APIs) from China, which is very strong in the manufacture of the same. However, China having curbed the export incentives for pharma exports amongst others (to control its trade surplus), the import of intermediates became expensive thereby leading to higher raw material costs. That said, had it not been for the rupee appreciation, the raw material expenses would have risen further.

    The top gainers and laggards...
    While the BSE-Sensex gained 26% in FY08, the four stocks (under our research coverage), which managed to beat the index, were Glenmark, Sun Pharma, Ranbaxy and Nicholas Piramal, in that order. Investors flocked to Glenmark, as the company was successful in clinching an out-licensing deal for its third molecule GRC 6211 for pain management with Eli Lilly. Besides this, the company also reported superlative growth in revenues and profits in 9mFY08. Sun Pharma gained favour due to its consistent results despite the uncertainty surrounding the Taro acquisition. Ranbaxy was in the limelight due to the company having settled patent suits for three blockbuster drugs, which has ensured that the company has atleast one first-to-file opportunity every year till 2010. Ramp up in its custom manufacturing business and improvement in the domestic market led to Nicholas Piramal notching strong gains.

    Meanwhile, Aventis was the worst performer of the lot as a slump in exports, lack of product launches and declining margins weighed heavy on the company's performance during CY07. Wockhardt also declined sharply, which could probably be attributed to the concerns surrounding the integration of the two acquisitions made by the company during the year and possible marked to market forex losses.

    Looking ahead...
    Overall we reiterate our positive view on the pharma sector as a whole despite the various challenges that this sector continues to face. We expect partnerships in generics, CRAMS, R&D and in-licensing to be the key growth drivers going forward. Having said that, investors need to adopt a stock specific approach while investing in this sector.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: The year that was…". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS